Introduction Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. In the United States, it was available in both prescription and over-the-counter forms and was widely prescribed by doctors. Unfortunately, in 2020, the Food and Drug Administration (FDA) announced the recall of Etodolac due to concerns over its safety. In this article, we will explore why this popular pain medication was discontinued and what this means for doctors and patients alike.
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that was used to treat mild to moderate pain and inflammation. It was available both as a prescription medication and as an over-the-counter medication. It was widely prescribed by doctors for a variety of conditions including arthritis, menstrual cramps, and other musculoskeletal conditions.
The FDA announced the recall of Etodolac in 2020 due to safety concerns. The FDA noted that the drug had been associated with an increased risk of serious cardiovascular events, including heart attack and stroke. Additionally, the FDA noted that the drug had been associated with an increased risk of gastrointestinal bleeding. As a result, the FDA determined that the risks associated with Etodolac outweighed the benefits and recommended that it be discontinued.
For doctors, the discontinuation of Etodolac means that they can no longer prescribe it to their patients. However, doctors can still prescribe other NSAIDs to treat pain and inflammation. Additionally, doctors should be aware of the potential risks associated with other NSAIDs and should only prescribe them when the benefits outweigh the risks. For patients, the discontinuation of Etodolac means that they may need to find an alternative medication to treat their pain and inflammation. Patients should speak to their doctor about other options that may be available to them. Additionally, patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. Unfortunately, in 2020, the FDA announced the recall of Etodolac due to safety concerns. This means that doctors can no longer prescribe it to their patients and patients may need to find an alternative medication to treat their pain and inflammation. Doctors and patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
1.
Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer
2.
GLP-1 receptor agonists show anti-cancer benefits beyond weight loss
3.
MGRS Relapse-Free Survival Better With Maintenance Therapy
4.
New protein target discovered for childhood medulloblastomas
5.
The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.
1.
Essential Updates in Hematology in Daily Practice
2.
Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics
3.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
4.
Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer
5.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
1.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Symposium on Oncology, Cardiology and Critical Care Innovations
4.
International Conference on Cancer Nursing and Hematology Support
5.
International Conference on Clinical Medicine and Surgical Care
1.
Understanding Common Causes of Abnormal Blood Counts
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
Understanding Blood Disorders and Their Diagnosis
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation